Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Primary Lymphoid Organs01:16

Primary Lymphoid Organs

14.4K
Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
14.4K
Secondary Lymphoid Organs01:15

Secondary Lymphoid Organs

8.6K
Secondary organs, including lymph nodes, the spleen, and mucosa-associated lymphoid tissue (MALT), work harmoniously to protect us from disease and infection.
The spleen is a vital organ in the lymphatic system, nestled in the upper left side of the abdomen. It is composed of two primary regions: the red pulp and the white pulp, each having distinct functions. The red pulp performs a significant role in blood filtration. It efficiently purges the blood of old or damaged red blood cells and...
8.6K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

6.3K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
6.3K
Skin Cancer01:30

Skin Cancer

5.6K
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
5.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.5K
Lymphoid Cells and Tissues01:18

Lymphoid Cells and Tissues

2.7K
Lymphoid cells and tissues are integral to the immune system, which is crucial in maintaining our body's defense against harmful pathogens. They form the building blocks of lymphoid organs, which include the spleen, thymus, and lymph nodes.
Lymphoid cells consist of various types of immune system cells. These include B and T lymphocytes, which are responsible for producing antibodies and killing infected cells, respectively. Dendritic cells act as messengers between the innate and adaptive...
2.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Deep survival learning for prognosis prediction in non-metastatic castration-resistant prostate cancer.

Health informatics journal·2026
Same author

Refractory Periorbital Necrobiotic Xanthogranuloma Treated With Plasma Cell-Directed Therapy.

EJHaem·2026
Same author

Autoimmune HLA alleles and neoantigens predict myelodysplastic syndrome outcomes after allogeneic HSCT: A CIBMTR analysis.

iScience·2026
Same author

Characteristics of women Veterans with incident breast and gynecologic cancers in the Veterans Health Administration.

Women's health (London, England)·2025
Same author

Using Open-Source Large Language Models to Identify Access to Germline Genetic Testing in Veterans With Breast Cancer From Unstructured Text.

JCO clinical cancer informatics·2025
Same author

Contextualizing results of randomized trials in smoldering myeloma.

The oncologist·2025

Related Experiment Video

Updated: Dec 22, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.5K

NCCN Guidelines Insights: Primary Cutaneous Lymphomas, Version 2.2020.

Neha Mehta-Shah1, Steven M Horwitz2, Stephen Ansell3

  • 1Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine.

Journal of the National Comprehensive Cancer Network : JNCCN
|May 8, 2020
PubMed
Summary
This summary is machine-generated.

Mycosis fungoides (MF) and Sézary syndrome (SS) are types of cutaneous T-cell lymphoma (CTCL). Advanced stages often require systemic therapy, with newer agents now available for treatment.

More Related Videos

Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling
09:08

Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling

Published on: October 14, 2021

6.1K
Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

11.8K

Related Experiment Videos

Last Updated: Dec 22, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.5K
Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling
09:08

Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling

Published on: October 14, 2021

6.1K
Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

11.8K

Area of Science:

  • Oncology
  • Dermatology
  • Hematology

Background:

  • Mycosis fungoides (MF) is the most common cutaneous T-cell lymphoma (CTCL).
  • Sézary syndrome (SS) is a rare, aggressive erythrodermic and leukemic subtype of CTCL with blood involvement.
  • Early-stage CTCL is typically managed with skin-directed therapies, while advanced stages necessitate systemic treatment.

Purpose of the Study:

  • To provide insights into the diagnosis and management of MF and SS.
  • To focus on the evolving landscape of systemic therapy for advanced CTCL.
  • To discuss the role of recently approved novel agents in CTCL treatment.

Main Methods:

  • Review of current literature and clinical guidelines.
  • Analysis of diagnostic criteria for MF and SS.
  • Evaluation of systemic treatment options, including novel agents.

Main Results:

  • Systemic therapy is crucial for advanced MF and SS.
  • Novel agents like romidepsin, brentuximab vedotin, and mogamulizumab represent significant advancements.
  • NCCN Guidelines provide a framework for managing these conditions.

Conclusions:

  • Effective management of MF and SS requires a comprehensive approach.
  • Systemic therapies, particularly novel agents, have improved treatment outcomes for advanced CTCL.
  • Adherence to updated NCCN Guidelines is essential for optimal patient care.